Developmental Disabilities Task News Today

When a politician makes the decision to accept a vice presidential or lieutenant governor invitation, it generally means taking on a subservient posture. All the time.

A proposal by Indiana Medicaid officials would drastically cut payments that thousands of families of people with disabilities relied on. State officials say its necessary to curb ballooning utilization and plug a huge budget gap. But some families worry the changes could lead to them losing their jobs or even their homes.

A proposal by Indiana Medicaid officials would drastically cut payments that thousands of families of people with disabilities relied on. State officials say it's necessary to curb ballooning utilization and plug a huge budget gap. But some families worry the changes could lead to them losing their jobs or even their homes.

Families of medically complex children say proposed Medicaid cuts would take away a vital caregiving resource. House Democrats say these families shouldnt pay the price for the Medicaid shortfall. They want Republican leaders to protect the attendant care program.

When a politician makes the decision to accept a vice presidential or lieutenant governor invitation, it generally means taking on a subservient posture. All the time.

INDIANAPOLIS ­— When a politician makes the decision to accept a vice presidential or lieutenant governor invitation, it generally means taking on a subservient posture. All the time. …

When a politician makes the decision to accept a vice presidential or lieutenant governor slot, it generally means taking on a subservient posture.

The Family and Social Services Administration in January announced it will end the attendant care program for legally responsible individuals.

The Family and Social Services Administration found its attendant care program expenses had roughly doubled to $120 million in six months.

The Centers for Medicare and Medicaid Services will pursue so-called outcomes-based agreements that would put discounts or rebates in place on two new expensive gene therapies if they don't deliver promised results for patients with sickle cell disease.